Experiments conducted on worms, zebrafish, mice and, finally, on human subjects in a limited clinical trial conclude that pimozide may be effective in treating what’s known as “Lou Gehrig’s disease.”
Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
An article published today in JCI Insight concludes that pimozide was found to be safe and over the short term, preliminary data shows that it could stabilize the progression of ALS. This neurodegenerative disease normally leads to a progressive paralysis of the skeletal muscles and, on average, three years after the onset of symptoms, to death.
“This medication alleviates the symptoms of ALS in animal models,” said Alex Parker, a CRCHUM researcher and professor at Université de Montréal. “Riluzole and edaravone, the drugs currently used, have modest effects. Other studies must be conducted to confirm our results, but we believe that we’ve found a medication that may prove to be more effective in improving patients’ quality of life.”
FROM WORM TO MAN
The story behind the discovery began six years ago with a little millimeter-long nematode worm called C. elegans. In his laboratory, Parker genetically modified the worms so that they would exhibit aspects of the human form of ALS. Simultaneously, his colleague Pierre Drapeau did the same thing to another animal, the zebrafish, a tiny tropical fish only 5 centimetres long.
The two scientists obtained funding from the U.S. Department of Defense to test medications on these worms and fish born with ALS. “We sifted through a library of 3,850 molecules approved for the treatment of other diseases, and found a class of antipsychotic drugs that stabilize mobility in worms and fish,” said Drapeau, a CRCHUM researcher, professor at Université de Montréal and principal investigator on the study. “Pimozide works especially well in preventing paralysis in fish by preserving the neuromuscular junction.”
Subsequently, Université de Montréal Professor Richard Robitaille performed electrophysiological tests on mice in his laboratory and reached the same conclusion. Thus, pimozide was shown to maintain neuromuscular function in three different animal models: worms, fish and mice.
At the annual ALS Canada Research Forum in 2012, the researchers met Dr. Lawrence Korngut, an Associate Professor at the CSM, member of the Hotchkiss Brain Institute (HBI) and Director of the Calgary ALS/Motor Neuron Disease Clinic. “Pimozide is a drug that has been well-known for 50 years,” the neurologist said. “It was approved for treating certain types of psychiatric conditions, like schizophrenia, and costs only 9 cents per pill. Other recent studies have shown genetic links between schizophrenia and ALS. The next logical step was to test it on human volunteers with ALS.”
In 2015, the first preclinical trial for ALS was launched in Canada with a small group of 25 patients who had ALS. Funding was provided by the Quirk family of Calgary, by the HBI, and the Clinical Research Unit at UCalgary.
“We found the highest dose most likely to be tolerated in individuals with ALS – a lower dose than that used in other conditions – and we have preliminary proof showing that pimozide may be useful,” said Korngut.
The initial clinical trial was modest in scope. But after only six weeks, the researchers had a first indication of the drug’s efficacy. Loss of control of the thenar muscles, located in the palm of the hand between thumb and index finger, is usually one of the first signs of ALS. For patients who took pimozide, this function remained stable. This observation is tempered by the very limited size and length of the clinical trial.
“For us, this is an indication that we found the right therapeutic target,” said Drapeau. “Pimozide acts directly on the neuromuscular junction, as shown in our animal models. We don’t yet know whether pimozide has a curative effect, or whether it only preserves normal neuromuscular function to at least stabilize the disease. This is also the first time that a potential drug for human patients was discovered based on basic research on small organisms such as worms and fish.”
Now comes the next step: a phase II clinical trial on 100 volunteers, funded by the “The Ice Bucket Challenge” through a partnership between ALS Canada and Brain Canada to begin in the next few weeks. Headed by Korngut in Calgary and conducted in nine hospital centres across Canada, the study aims to confirm that pimozide is safe and to measure, over a six-month period, its effect on the progression of the disease and its symptoms and on patients’ quality of life.
Daniel Rompré, 47, father of two teenage girls, hopes to participate in the new study. He was diagnosed with ALS in March 2016. The muscles of his upper body are getting weaker, he is beginning to have trouble speaking, and he can no longer use his left arm. “It is hard to maintain a positive outlook,” Rompré said. “You ask yourself: ‘Why me?’ But at least it’s encouraging to see that research is advancing. There has been more progress in the last five years than in 100 years of research on the disease.”
It is too soon to draw firm conclusions about the safety and efficacy of pimozide. “At this stage, people with ALS should not use this medication,” Korngut emphasized. “We must first confirm that it is really useful and safe in the longer term. It is also important to be aware that pimozide is associated with significant side effects. Therefore, it should only be prescribed in the context of a research study.”
The Latest on: Lou Gehrig’s disease
- A wife's complaints about nursing home's neglect led to probe, arrests on December 16, 2018 at 12:14 am
In describing Huntington's chorea, she said it's "a mixture of Lou Gehrig's disease and Parkinson's disease and that's like a death sentence." An avid golfer who loved the Buffalo Bills and ... […]
- Why being angry is all the rage in charitable giving this year on December 14, 2018 at 10:33 am
It’s possible for nonprofit work to “go viral” even if it doesn’t incite rage: The Ice Bucket Challenge to raise awareness of ALS, or Lou Gehrig’s disease, raised $115 million in funding for the ALS F... […]
- Gut-brain link? MSU scientists seek life-saving clues with $2.9 million grant on December 14, 2018 at 5:14 am
They’re working to figure out whether the cause of diseases like Alzheimer’s, Parkinson’s or Lou Gehrig’s disease could be linked to what’s going on in metabolism or the forest of microbes in the huma... […]
- Songs for Bronnie on December 14, 2018 at 4:08 am
She lives here with her husband, Stephen Martineau, who is telling me about navigating complex insurance mazes while helping his wife deal with the traumatic journey that is amyotrophic lateral sclero... […]
- This 102-year-old woman skydived to raise awareness for the disease that killed her daughter on December 12, 2018 at 5:00 am
In the United States, the disease is known as Lou Gehrig’s disease or amyotrophic lateral sclerosis. O’Shea’s bravery is a testament to both a mother’s unending love and her bottomless grief. “I lost ... […]
- Former NFL Player Tim Green Has A New Opponent — ALS on December 12, 2018 at 1:20 am
But a diagnosis in 2016 made denial impossible. Doctors confirmed that Tim, also a former NPR commentator, had ALS, known as Lou Gehrig's disease. The degenerative illness attacks the body's motor ner... […]
- Local boy has become CSI Baseball's biggest hero on December 10, 2018 at 11:41 pm
"It affects everything it does, if he gets sick, it's usually worse than most people. His condition is compared to Lou Gehrig's disease." College of Southern Idaho assistant baseball coach Nick Aiello ... […]
- Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows on December 10, 2018 at 9:11 pm
ALS - also called Lou Gehrig's disease or motor neuron disease - is a progressive neurodegenerative disorder that leads to the death of neurons in the brain and spinal cord. There are only three drugs ... […]
- Scientists May Have Halted Blindness Caused by This Rare Genetic Disease on December 8, 2018 at 1:22 pm
offering hope for patients with Huntington’s disease and amyotrophic lateral sclerosis, which is also known as Lou Gehrig’s disease. Given the recent success with ASO therapy (Spinraza) as a treatment ... […]
- CDC: Prevalence of neuromuscular disease ALS appears 'stable' on December 8, 2018 at 10:19 am
Forty institutions have received such approval to date. Sometimes referred to as Lou Gehrig's disease after the New York Yankee baseball player who developed it in 1939, ALS was the focus of a popular ... […]
via Google News and Bing News